TABLE 3.
Profile of adverse events.
| Adverse events | Adverse events, (N, %) | |
|---|---|---|
| Any grade | Grade ≥3 | |
| Hematological adverse event | ||
| Neutropenia | 8 (29.6) | 2 (7.4) |
| Leukopenia | 8 (29.6) | 2 (7.4) |
| Thrombocytopenia | 7 (25.9) | 3 (11.1) |
| Anemia | 15 (55.6) | 2 (7.4) |
| Non‐hematological adverse events | ||
| Cardiac creatine kinase level change | 2 (7.4) | 0 (0) |
| Nausea or vomiting | 12 (44.4) | 1 (3.7) |
| Immune‐related adverse events | ||
| Reactive cutaneous capillary endothelial proliferation | 11 (40.7) | 0 (0) |
| Liver injury a | 9 (33.3) | 1 (3.7) |
| Kidney injury | 3 (11.1) | 0 (0) |
| Hypothyroidism | 2 (7.4) | 0 (0) |
| Diarrhea and colitis | 0 (0) | 0 (0) |
a
One patient was considered immune‐related hepatitis.